Reconnecting

The current page stays visible while onset.to reconnects in the background.

Health Canada authorizes Optimi's natural psilocybin depression trial as a US House bill considers 12-year botanical drug exclusivity

Open original

Health Canada has authorized Optimi Health to conduct a multisite Phase 2 trial testing one supervised dose of naturally derived psilocybin in up to 200 adults with major depressive disorder. The study is expected to begin in the first half of 2027 and finish dosing by year end, with change on the Montgomery-Åsberg Depression Rating Scale as its primary efficacy endpoint. The authorization permits research but does not approve the product or expand general access, and key details including dose, comparator, sites, and psychological support remain undisclosed. The report also examines the US Advancing Botanical Drug Development Act of 2026, which would provide 12 years of exclusivity for qualifying botanical drugs. Its effect on mushroom-derived medicines is uncertain because eligibility would depend on future HHS rules distinguishing broad botanical extracts from highly purified compounds. Optimi would need to pursue US approval for the provision to apply.